Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2012

01.02.2012 | Original Article

Risk of Ulcerative Colitis-Associated Colorectal Cancer in China: A Multi-Center Retrospective Study

verfasst von: Wei Gong, Nonghua Lv, Bangmao Wang, Ye Chen, Yinglong Huang, Wenshen Pan, Bo Jiang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The number of patients with ulcerative colitis (UC) in China has increased in the past 10 years. Thus, it is anticipated that the incidence of UC-associated colorectal cancer (UC-CRC) will also increase. However, the risk of CRC in UC patients is still unknown in Chinese. The aim of this study was to identify the risk and risk factors of UC-CRC in Chinese.

Methods

A total of 3,922 patients with UC were retrospectively collected from five central teaching hospitals in China, in which high-quality endoscopic and histological diagnoses were available from 1998 to 2009. The database of the UC and UC-associated CRC patients was evaluated.

Results

CRC was diagnosed 34 in patients, and the overall prevalence of CRC in patients with UC was 0.87%. The cumulative risk of developing CRC after a disease duration of 10 years was 1.15% (95% confidence interval [CI] 0.71–1.84%); 20 years, 3.56% (95% CI 2.14–5.89%); and 30 years, 14.36% (95% CI 7.57–26.3%). Longer disease duration, extensive colitis, and dysplasia found in the biopsy specimen were identified as risk factors for developing CRC. 5-ASA use was identified as a protective factor of UC-CRC.

Conclusions

The period prevalence of CRC was lower than that reported from the West. However, the cumulative risk was found to be comparable to that of Western countries, which suggests that the period prevalence of UC-CRC in China may be growing in the future.
Literatur
1.
Zurück zum Zitat Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:1–5.PubMedCrossRef Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:1–5.PubMedCrossRef
2.
Zurück zum Zitat Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;7:3937–3947.CrossRef Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;7:3937–3947.CrossRef
3.
Zurück zum Zitat Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170:220–228.CrossRef Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170:220–228.CrossRef
4.
Zurück zum Zitat Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.PubMedCrossRef Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.PubMedCrossRef
5.
Zurück zum Zitat Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer surveillance in ulcerative colitis: experience over 15 years. Lancet. 1983;2:149–152.PubMedCrossRef Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer surveillance in ulcerative colitis: experience over 15 years. Lancet. 1983;2:149–152.PubMedCrossRef
6.
Zurück zum Zitat Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:24–30.PubMedCrossRef Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:24–30.PubMedCrossRef
7.
Zurück zum Zitat Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233.PubMedCrossRef Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233.PubMedCrossRef
8.
Zurück zum Zitat Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047–1052.PubMed Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047–1052.PubMed
9.
Zurück zum Zitat Maratka Z, Nedbal J, Kocianova J, et al. Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years. Gut. 1985;26:43–49.PubMedCrossRef Maratka Z, Nedbal J, Kocianova J, et al. Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years. Gut. 1985;26:43–49.PubMedCrossRef
10.
Zurück zum Zitat Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35:517–531.PubMedCrossRef Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35:517–531.PubMedCrossRef
11.
Zurück zum Zitat Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205–211.PubMedCrossRef Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205–211.PubMedCrossRef
12.
Zurück zum Zitat Kim BJ, Yang SK, Kim JS, et al. Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol. 2009;24:667–671.PubMedCrossRef Kim BJ, Yang SK, Kim JS, et al. Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol. 2009;24:667–671.PubMedCrossRef
13.
Zurück zum Zitat Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–709.PubMedCrossRef Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–709.PubMedCrossRef
14.
Zurück zum Zitat Jiang L, Xia B, Li J, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis. 2006;12:212–217.PubMedCrossRef Jiang L, Xia B, Li J, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis. 2006;12:212–217.PubMedCrossRef
15.
Zurück zum Zitat Yun J, Xu CT, Pan BR. Epidemiology and gene markers of ulcerative colitis in the Chinese. World J Gastroenterol. 2009;15:788–803.PubMedCrossRef Yun J, Xu CT, Pan BR. Epidemiology and gene markers of ulcerative colitis in the Chinese. World J Gastroenterol. 2009;15:788–803.PubMedCrossRef
16.
Zurück zum Zitat Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24:2–6.CrossRef Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24:2–6.CrossRef
17.
Zurück zum Zitat Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc. 1996;44:8–14.PubMedCrossRef Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc. 1996;44:8–14.PubMedCrossRef
18.
Zurück zum Zitat Hendriksen C, Kreiner S, Binder V. Long-term prognosis in ulcerative colitis based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:158–163.PubMedCrossRef Hendriksen C, Kreiner S, Binder V. Long-term prognosis in ulcerative colitis based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:158–163.PubMedCrossRef
19.
Zurück zum Zitat Kewenter J, Ahlman H, Hulten L. Cancer risk in extensive ulcerative colitis. Ann Surg. 1978;188:824–828.PubMedCrossRef Kewenter J, Ahlman H, Hulten L. Cancer risk in extensive ulcerative colitis. Ann Surg. 1978;188:824–828.PubMedCrossRef
20.
Zurück zum Zitat Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.PubMedCrossRef Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.PubMedCrossRef
21.
Zurück zum Zitat Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–1105. quiz 1340-1341.PubMedCrossRef Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–1105. quiz 1340-1341.PubMedCrossRef
22.
Zurück zum Zitat Brown JB, Lee G, Managlia E, et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010;138:595–605.PubMedCrossRef Brown JB, Lee G, Managlia E, et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010;138:595–605.PubMedCrossRef
23.
Zurück zum Zitat Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):367–371.PubMedCrossRef Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):367–371.PubMedCrossRef
24.
Zurück zum Zitat Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784–2788.PubMedCrossRef Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784–2788.PubMedCrossRef
25.
Zurück zum Zitat Shanahan F. Review article: colitis-associated cancer—time for new strategies. Aliment Pharmacol Ther. 2003;18:6–9.PubMedCrossRef Shanahan F. Review article: colitis-associated cancer—time for new strategies. Aliment Pharmacol Ther. 2003;18:6–9.PubMedCrossRef
26.
Zurück zum Zitat Eaden JA, Mayberry JF, British Society for Gastroenterology, Association of Coloproctology for Great Britain, Ireland. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10–V12.PubMedCrossRef Eaden JA, Mayberry JF, British Society for Gastroenterology, Association of Coloproctology for Great Britain, Ireland. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10–V12.PubMedCrossRef
27.
Zurück zum Zitat Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.PubMedCrossRef Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.PubMedCrossRef
28.
Zurück zum Zitat Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.PubMedCrossRef Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.PubMedCrossRef
29.
Zurück zum Zitat Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology. 1994;107:117–120.PubMed Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology. 1994;107:117–120.PubMed
Metadaten
Titel
Risk of Ulcerative Colitis-Associated Colorectal Cancer in China: A Multi-Center Retrospective Study
verfasst von
Wei Gong
Nonghua Lv
Bangmao Wang
Ye Chen
Yinglong Huang
Wenshen Pan
Bo Jiang
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1890-9

Weitere Artikel der Ausgabe 2/2012

Digestive Diseases and Sciences 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.